Clinicopathlogic and Immunohistochemical Characteristics of Triple Negative Invasive Lobular Carcinoma.
- Author:
Ja Seung KOO
1
;
WooHee JUNG
Author Information
- Publication Type:Original Article
- Keywords: Carcinoma; lobular; triple negative breast cancer
- MeSH: Adult; Breast Neoplasms/*metabolism; Cadherins/metabolism; Carcinoma, Lobular/*metabolism; Female; Galectin 3/metabolism; Humans; Immunohistochemistry/*methods; Keratin-5/metabolism; Keratin-6/metabolism; Middle Aged; Proto-Oncogene Proteins c-kit/metabolism; Receptor, Epidermal Growth Factor/metabolism; Receptors, Androgen; Receptors, Estrogen/metabolism; Receptors, Progesterone/metabolism; Vimentin/metabolism
- From:Yonsei Medical Journal 2011;52(1):89-97
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Our study is performed to find out clinicopathlogic and immunohistochemical (IHC) characteristics of triple negative invasive lobular carcinoma (ILC), as has been demonstrated in their invasive ductal counterparts. MATERIALS AND METHODS: Retrospective analysis of variable clinicopathlogic parameters and IHC stains for androgen receptor, estrogen receptor, progesterone receptor, p53, c-kit, galectin-3, cytokeratin 5 (CK5), CK5/6, vimentin, E-cadherin, epidermal growth factor receptor, and HER2 were performed in 117 cases of ILC. RESULTS: Eight cases (6.8%) were triple negative carcinoma (TNC), which showed higher incidence of high histologic grade than non-TNC (p = 0.019). Galectin-3 was expressed with higher incidence in tumor cells of TNC (62.5%) than those of non-TNC (7.3%) (p = 0.000). In contrast, galectin-3 was expressed with higher incidence in stromal cells of non-TNC (53.2%) than those of TNC (12.5%) (p = 0.029). CK5 and CK5/6 were not expressed in all ILCs. CONCLUSION: TNC in ILC showed distinct clinicopathologic and IHC characteristics such as higher histologic grade and increased expression of galectin-3, compared to non-TNC in ILC. TNC in ILC was less frequent and did not show CK5 and CK5/6 expression when compared to TNC in invasive ductal carcinoma.
